These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 29023112)

  • 1. Design of Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors Using a Crystallographic Surrogate Derived from Checkpoint Kinase 1 (CHK1).
    Williamson DS; Smith GP; Acheson-Dossang P; Bedford ST; Chell V; Chen IJ; Daechsel JCA; Daniels Z; David L; Dokurno P; Hentzer M; Herzig MC; Hubbard RE; Moore JD; Murray JB; Newland S; Ray SC; Shaw T; Surgenor AE; Terry L; Thirstrup K; Wang Y; Christensen KV
    J Med Chem; 2017 Nov; 60(21):8945-8962. PubMed ID: 29023112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and Synthesis of Pyrrolo[2,3-
    Williamson DS; Smith GP; Mikkelsen GK; Jensen T; Acheson-Dossang P; Badolo L; Bedford ST; Chell V; Chen IJ; Dokurno P; Hentzer M; Newland S; Ray SC; Shaw T; Surgenor AE; Terry L; Wang Y; Christensen KV
    J Med Chem; 2021 Jul; 64(14):10312-10332. PubMed ID: 34184879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MLi-2, a Potent, Selective, and Centrally Active Compound for Exploring the Therapeutic Potential and Safety of LRRK2 Kinase Inhibition.
    Fell MJ; Mirescu C; Basu K; Cheewatrakoolpong B; DeMong DE; Ellis JM; Hyde LA; Lin Y; Markgraf CG; Mei H; Miller M; Poulet FM; Scott JD; Smith MD; Yin Z; Zhou X; Parker EM; Kennedy ME; Morrow JA
    J Pharmacol Exp Ther; 2015 Dec; 355(3):397-409. PubMed ID: 26407721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting leucine-rich repeat kinase 2 (LRRK2) for the treatment of Parkinson's disease.
    Domingos S; Duarte T; Saraiva L; Guedes RC; Moreira R
    Future Med Chem; 2019 Aug; 11(15):1953-1977. PubMed ID: 31517532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).
    Galatsis P
    Expert Opin Ther Pat; 2017 Jun; 27(6):667-676. PubMed ID: 28117607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery and preclinical profiling of 3-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile (PF-06447475), a highly potent, selective, brain penetrant, and in vivo active LRRK2 kinase inhibitor.
    Henderson JL; Kormos BL; Hayward MM; Coffman KJ; Jasti J; Kurumbail RG; Wager TT; Verhoest PR; Noell GS; Chen Y; Needle E; Berger Z; Steyn SJ; Houle C; Hirst WD; Galatsis P
    J Med Chem; 2015 Jan; 58(1):419-32. PubMed ID: 25353650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Leucine-rich repeat kinase 2 inhibitors: a review of recent patents (2011 - 2013).
    Kethiri RR; Bakthavatchalam R
    Expert Opin Ther Pat; 2014 Jul; 24(7):745-57. PubMed ID: 24918198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of LRRK2 Inhibitors for the Treatment of Parkinson's Disease.
    Christensen KV; Smith GP; Williamson DS
    Prog Med Chem; 2017; 56():37-80. PubMed ID: 28314412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of G2019S-Selective Leucine Rich Repeat Protein Kinase 2 inhibitors with in vivo efficacy.
    Leśniak RK; Nichols RJ; Schonemann M; Zhao J; Gajera CR; Fitch WL; Lam G; Nguyen KC; Smith M; Montine TJ
    Eur J Med Chem; 2022 Feb; 229():114080. PubMed ID: 34992038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LRRK2 G2019S-induced mitochondrial DNA damage is LRRK2 kinase dependent and inhibition restores mtDNA integrity in Parkinson's disease.
    Howlett EH; Jensen N; Belmonte F; Zafar F; Hu X; Kluss J; Schüle B; Kaufman BA; Greenamyre JT; Sanders LH
    Hum Mol Genet; 2017 Nov; 26(22):4340-4351. PubMed ID: 28973664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of novel indolinone-based, potent, selective and brain penetrant inhibitors of LRRK2.
    Troxler T; Greenidge P; Zimmermann K; Desrayaud S; Drückes P; Schweizer T; Stauffer D; Rovelli G; Shimshek DR
    Bioorg Med Chem Lett; 2013 Jul; 23(14):4085-90. PubMed ID: 23768909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective Inhibitors of G2019S-LRRK2 Kinase Activity.
    Garofalo AW; Bright J; De Lombaert S; Toda AMA; Zobel K; Andreotti D; Beato C; Bernardi S; Budassi F; Caberlotto L; Gao P; Griffante C; Liu X; Mengatto L; Migliore M; Sabbatini FM; Sava A; Serra E; Vincetti P; Zhang M; Carlisle HJ
    J Med Chem; 2020 Dec; 63(23):14821-14839. PubMed ID: 33197196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decoding Inhibitor Egression from Wild-Type and G2019S Mutant LRRK2 Kinase: Insights into Unbinding Mechanisms for Precision Drug Design in Parkinson's Disease.
    Naskar A; Roy RK; Srivastava D; Patra N
    J Phys Chem B; 2024 Jul; 128(28):6657-6669. PubMed ID: 38822803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor.
    Reith AD; Bamborough P; Jandu K; Andreotti D; Mensah L; Dossang P; Choi HG; Deng X; Zhang J; Alessi DR; Gray NS
    Bioorg Med Chem Lett; 2012 Sep; 22(17):5625-9. PubMed ID: 22863203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential Inhibition of LRRK2 in Parkinson's Disease Patient Blood by a G2019S Selective LRRK2 Inhibitor.
    Bright JM; Carlisle HJ; Toda AMA; Murphy M; Molitor TP; Wren P; Andruska KM; Liu E; Barlow C
    Mov Disord; 2021 Jun; 36(6):1362-1371. PubMed ID: 33836114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of a 3-(4-Pyrimidinyl) Indazole (MLi-2), an Orally Available and Selective Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitor that Reduces Brain Kinase Activity.
    Scott JD; DeMong DE; Greshock TJ; Basu K; Dai X; Harris J; Hruza A; Li SW; Lin SI; Liu H; Macala MK; Hu Z; Mei H; Zhang H; Walsh P; Poirier M; Shi ZC; Xiao L; Agnihotri G; Baptista MA; Columbus J; Fell MJ; Hyde LA; Kuvelkar R; Lin Y; Mirescu C; Morrow JA; Yin Z; Zhang X; Zhou X; Chang RK; Embrey MW; Sanders JM; Tiscia HE; Drolet RE; Kern JT; Sur SM; Renger JJ; Bilodeau MT; Kennedy ME; Parker EM; Stamford AW; Nargund R; McCauley JA; Miller MW
    J Med Chem; 2017 Apr; 60(7):2983-2992. PubMed ID: 28245354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leucine-rich repeat kinase 2 inhibitors: a patent review (2006 - 2011).
    Deng X; Choi HG; Buhrlage SJ; Gray NS
    Expert Opin Ther Pat; 2012 Dec; 22(12):1415-26. PubMed ID: 23126385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploring the functional impact of mutational drift in LRRK2 gene and identification of specific inhibitors for the treatment of Parkinson disease.
    Nagarajan N; Chellam J; Kannan RR
    J Cell Biochem; 2018 Jun; 119(6):4878-4889. PubMed ID: 29369408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interrogating Parkinson's disease LRRK2 kinase pathway activity by assessing Rab10 phosphorylation in human neutrophils.
    Fan Y; Howden AJM; Sarhan AR; Lis P; Ito G; Martinez TN; Brockmann K; Gasser T; Alessi DR; Sammler EM
    Biochem J; 2018 Jan; 475(1):23-44. PubMed ID: 29127255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The G2019S mutation in LRRK2 imparts resiliency to kinase inhibition.
    Kelly K; Wang S; Boddu R; Liu Z; Moukha-Chafiq O; Augelli-Szafran C; West AB
    Exp Neurol; 2018 Nov; 309():1-13. PubMed ID: 30048714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.